阅读说明：本技术 Rps6ka1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 (RPS6KA1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit ) 是由 李为民 张立 于 2019-07-31 设计创作，主要内容包括：本发明涉及体外诊断试剂领域,具体涉及RPS6KA1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途。本发明首次发现肺癌患者血清中RPS6KA1蛋白的自身抗体水平显著高于健康患者。本发明将检测RPS6KA1蛋白自身抗体的试剂用于制备肺癌筛查试剂盒,能够实现肺癌的有效筛查。(The present invention relates to external diagnosis reagent fields, and in particular to RPS6KA1 autoantibody detection reagent is preparing the purposes in screening lung cancer kit.Present invention firstly discovers that the autoantibody of RPS6KA1 albumen is significantly higher than healthy patients in Serum of Patients with Lung Cancer.The reagent that the present invention will test RPS6KA1 albumen autoantibody is used to prepare screening lung cancer kit, can be realized effective screening of lung cancer.)

1. the reagent of detection RPS6KA1 albumen autoantibody is preparing the purposes in screening lung cancer kit.

2. purposes as described in claim 1, which is characterized in that the reagent of the detection RPS6KA1 albumen autoantibody is enzyme Linked immunosorbent adsorption test reagent or linked immune analysis reagent.

3. purposes as described in claim 1, which is characterized in that it is described detection RPS6KA1 albumen autoantibody reagent be Western blot reagent.

4. purposes as described in claim 1, which is characterized in that the reagent of the detection RPS6KA1 albumen autoantibody is egg White chip detecting method reagent.

5. the purposes as described in Claims 1 to 4 is any, which is characterized in that the examination of the detection RPS6KA1 albumen autoantibody Agent is the reagent for detecting RPS6KA1 albumen autoantibody in human serum.

6. a kind of screening lung cancer kit, which is characterized in that it includes the reagent for detecting RPS6KA1 albumen autoantibody.

7. kit as claimed in claim 6, which is characterized in that it is described detection RPS6KA1 albumen autoantibody reagent be Enzyme-linked immunosorbent assay reagent or ELISA reagent.

8. kit as claimed in claim 6, which is characterized in that it is described detection RPS6KA1 albumen autoantibody reagent be Western blot reagent.

9. kit as claimed in claim 6, which is characterized in that it is described detection RPS6KA1 albumen autoantibody reagent be Protein chip detection method reagent.

10. the kit as described in claim 5~9 is any, which is characterized in that the detection RPS6KA1 albumen autoantibody Reagent be detect human serum in RPS6KA1 albumen autoantibody reagent.

Technical field

The present invention relates to external diagnosis reagent fields, and in particular to RPS6KA1 autoantibody detection reagent is in preparation lung cancer Purposes in kit for screening.

Background technique

Lung cancer is that one of most common malignant tumour, morbidity and mortality are in rise year by year trend in the world, at present Disease incidence occupies first place in the world, and seriously threatens human health and life.

Lung cancer is a kind of disease for being good at concealment, often develops to advanced stage in disease and just shows clinical symptoms, 70~ 80% patients with lung cancer has been middle and advanced stage when being diagnosed to be with Lung Cancer Symptoms, and cancer cell has been spread, and misses best healing Opportunity, five year survival rate are low.For the patients with lung cancer of early stage, giving birth to for 5 years or more for patient is greatly improved by treating in time Deposit rate and life quality.Therefore the early diagnosis and the effective screening of progress of lung cancer are most important.

The screening of lung cancer, referring to does not have the related indication crowd of lung cancer to carry out routine physical examination those, before there is symptom Discovery lung cancer in time.If the lung cancer molecular marker inside blood plasma can be found, for prompting clinician's early stage to patient Relevant remedy measures or decision are taken to have great importance.

Autoantibody refers to the antibody that body generates itself organ, cell or cell component.Currently, certain albumen from Body antibody has become the marker of lung cancer, such as: p53, NY-ESO-1, CYFRA (Tang Z-M, Ling Z-G, Wang C-M, Wu Y-B, Kong J-L (2017) Serum tumor-associated autoantibodies as diagnostic Biomarkers for lung cancer:A systematic review and meta-analysis.PLoS ONE 12 (7): e0182117).

RSK (the ribosomes of RPS6KA1 gene (Ensembl: ENSG00000117676) encoding serine/threonine kinase S6 kinase) family member.The kinases contains 2 different kinase catalytic domains, and the various substrates of phosphorylation, including mitogen The member of former activated protein kinase (MAPK) signal path.

The currently reported RSK1 for claiming RSK protein family can promote growth and the transfer (RSK1 of mouse breast cancer promotes murine breast cancer growth and metastasis.Folia Histochem Cytobiol.2018；56 (1): 11-20.)；But the relevant report for having not yet to see RPS6KA1 albumen autoantibody, also has no The RPS6KA1 albumen autoantibody prior art relevant to lung cancer.

Summary of the invention

The purpose of the present invention is to provide the detections of the lung cancer marker and the marker of a kind of new autoantibody class Reagent is preparing the purposes in screening lung cancer kit.

Technical solution of the present invention includes:

The reagent of detection RPS6KA1 albumen autoantibody is preparing the purposes in screening lung cancer kit.

Purposes as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are enzyme-linked immunosorbent assay examination Agent or linked immune analysis reagent.

The reagent of purposes as the aforementioned, the detection RPS6KA1 albumen autoantibody is western blot reagent.

Purposes as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are the examination of protein chip detection method Agent.

Purposes as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are RPS6KA1 eggs in detection human serum The reagent of white autoantibody.

A kind of screening lung cancer kit, it includes the reagent for detecting RPS6KA1 albumen autoantibody.

Kit as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are enzyme-linked immunosorbent assay use Reagent or ELISA reagent.

The reagent of kit as the aforementioned, the detection RPS6KA1 albumen autoantibody is western blot reagent.

Kit as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are protein chip detection method use Reagent.

Kit as the aforementioned, the reagent of the detection RPS6KA1 albumen autoantibody are RPS6KA1 in detection human serum The reagent of albumen autoantibody.

The present invention provides a kind of new screening lung cancer markers and a kind of new screening lung cancer kit, can be realized lung Effective screening of cancer；And patient can be injured very low using serum as test sample.

The kit can also distinguish lung's benign disease and lung cancer.

Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.

Above content of the invention is described in further detail again below by way of specific embodiment.But it should not be by this The range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below.All technologies realized based on above content of the present invention are equal Belong to the scope of the present invention.

Hereinafter " RPS6KA1 autoantibody " refers to " RPS6KA1 albumen autoantibody ".

Detailed description of the invention

Fig. 1: patients with lung cancer (LC), lung's benign disease (DC), normal healthy controls (NC) serum slurry in RPS6KA1 autoantibody Level comparison.

Fig. 2: patients with lung cancer (LC) and lung's benign disease (DC) ROC are analyzed.

Fig. 3: patients with lung cancer (LC) and normal healthy controls (NC) ROC are analyzed.

Specific embodiment